Martin Rhee, MD

Gilead Sciences
Foster City, California, United States

Disclosure(s): Gilead Sciences, Inc.: employee and shareholder

Presentation(s):

• 155 - Long-Acting Subcutaneous Lenacapavir in People with Multi-Drug Resistant HIV-1: 3-Year Results of the CAPELLA Study

  Thursday, October 17, 2024
  2:00 PM – 2:15 PM US PT

• 577 - Week 48 Results of a Phase 2 Study Evaluating Once-weekly Oral Islatravir Plus Lenacapavir

  Saturday, October 19, 2024
  2:09 PM – 2:21 PM US PT